{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:52:43Z","timestamp":1792601563373,"version":"4.5.0"},"reference-count":231,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T00:00:00Z","timestamp":1685059200000},"content-version":"am","delay-in-days":329,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.blre.2022.100932","type":"journal-article","created":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T17:42:05Z","timestamp":1643823725000},"page":"100932","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Endothelial cells: major players in acute myeloid leukaemia"],"prefix":"10.1016","volume":"54","author":[{"given":"Sofiane","family":"Fodil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Arnaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Vaganay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Puissant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Lengline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuala","family":"Mooney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Itzykson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Zafrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2022.100932_bb0005","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","article-title":"Acute myeloid leukemia ontogeny is defined by distinct somatic mutations","volume":"125","author":"Lindsley","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.100932_bb0010","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nature13968","article-title":"Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia","volume":"518","author":"Wong","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.blre.2022.100932_bb0015","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.100932_bb0020","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11912-020-0885-0","article-title":"Acute myeloid leukaemia in its niche: the bone marrow microenvironment in acute myeloid leukaemia","volume":"22","author":"Ladikou","year":"2020","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.blre.2022.100932_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10428199509064917","article-title":"Interaction of acute leukemia cells with the bone marrow microenvironment: implications for control of minimal residual disease","volume":"18","author":"Bradstock","year":"1995","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2022.100932_bb0030","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0145-2126(98)00156-8","article-title":"Expression and release of adhesion molecules by human acute myelogenous leukemia blasts","volume":"23","author":"Bruserud","year":"1999","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2022.100932_bb0035","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1182\/blood.V97.7.2121","article-title":"Endothelial cell activation by myeloblasts: molecular mechanisms of leukostasis and leukemic cell dissemination","volume":"97","author":"Stucki","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.100932_bb0040","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/bies.950161208","article-title":"Differentiation of endothelial cells: analysis of the constitutive and activated endothelial cell phenotypes","volume":"16","author":"Augustin","year":"1994","journal-title":"Bioessays"},{"key":"10.1016\/j.blre.2022.100932_bb0045","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.semnephrol.2012.02.002","article-title":"Endothelial control of vasomotor tone: the kidney perspective","volume":"32","author":"Lamas","year":"2012","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.blre.2022.100932_bb0050","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.eursup.2008.10.011","article-title":"A close look at the endothelium: its role in the regulation of vasomotor tone","volume":"8","author":"Mas","year":"2009","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.blre.2022.100932_bb0055","doi-asserted-by":"crossref","first-page":"302","DOI":"10.2174\/1874192401004010302","article-title":"The endothelium and its role in regulating vascular tone","volume":"4","author":"Sandoo","year":"2010","journal-title":"Open Cardiovasc Med J"},{"key":"10.1016\/j.blre.2022.100932_bb0060","first-page":"e90","article-title":"Thrombotic regulation from the endothelial cell perspectives","volume":"38","author":"Miao","year":"2018","journal-title":"Arterioscl Thromb Vasc Biol"},{"key":"10.1016\/j.blre.2022.100932_bb0065","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00281-011-0285-5","article-title":"Endothelium--role in regulation of coagulation and inflammation","volume":"34","author":"van Hinsbergh","year":"2012","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.blre.2022.100932_bb0070","doi-asserted-by":"crossref","DOI":"10.1186\/s12872-015-0124-z","article-title":"Endothelial cell control of thrombosis","volume":"15","author":"Yau","year":"2015","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.blre.2022.100932_bb0075","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5482\/HAMO-14-11-0075","article-title":"Endothelium and haemostasis","volume":"35","author":"Aird","year":"2015","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.blre.2022.100932_bb0080","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nrm3176","article-title":"Molecular control of endothelial cell behaviour during blood vessel morphogenesis","volume":"12","author":"Herbert","year":"2011","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.blre.2022.100932_bb0085","doi-asserted-by":"crossref","first-page":"H29","DOI":"10.1530\/VB-20-0007","article-title":"Endothelial cells on the move: dynamics in vascular morphogenesis and disease","volume":"2","author":"Fonseca","year":"2020","journal-title":"Vasc Biol"},{"key":"10.1016\/j.blre.2022.100932_bb0090","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/micc.12229","article-title":"Angiogenesis revisited: an overlooked role of endothelial cell metabolism in vessel sprouting","volume":"22","author":"Vandekeere","year":"2015","journal-title":"Microcirculation"},{"key":"10.1016\/j.blre.2022.100932_bb0095","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.51413","article-title":"Endothelial heterogeneity across distinct vascular beds during homeostasis and inflammation","volume":"9","author":"Jambusaria","year":"2020","journal-title":"Elife"},{"key":"10.1016\/j.blre.2022.100932_bb0100","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1038\/s41598-020-80102-w","article-title":"Tissue-specific endothelial cell heterogeneity contributes to unequal inflammatory responses","volume":"11","author":"Gunawardana","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.blre.2022.100932_bb0105","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S0022-2143(96)80012-6","article-title":"Isolation, characterization, and biologic features of bone marrow endothelial cells","volume":"128","author":"Almeida-Porada","year":"1996","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.blre.2022.100932_bb0110","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1182\/blood.V84.1.10.10","article-title":"Isolation and characterization of human bone marrow microvascular endothelial cells: hematopoietic progenitor cell adhesion","volume":"84","author":"Rafii","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.100932_bb0115","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1126\/science.7692600","article-title":"Binding of L-selectin to the vascular sialomucin CD34","volume":"262","author":"Baumheter","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.blre.2022.100932_bb0120","first-page":"25","article-title":"Characterization of a newly established human bone marrow endothelial cell line: distinct adhesive properties for hematopoietic progenitors compared with human umbilical vein endothelial cells","volume":"76","author":"Schweitzer","year":"1997","journal-title":"Lab Invest"},{"key":"10.1016\/j.blre.2022.100932_bb0125","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/0092-8674(91)90279-8","article-title":"Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity","volume":"67","author":"Butcher","year":"1991","journal-title":"Cell"},{"key":"10.1016\/j.blre.2022.100932_bb0130","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/0092-8674(94)90337-9","article-title":"Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm","volume":"76","author":"Springer","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.blre.2022.100932_bb0135","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1182\/blood-2018-12-844605","article-title":"Neutrophil transendothelial migration: updates and new perspectives","volume":"133","author":"Filippi","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.100932_bb0140","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.immuni.2014.10.008","article-title":"Leukocyte migration into inflamed tissues","volume":"41","author":"Nourshargh","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.blre.2022.100932_bb0145","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/imr.12443","article-title":"Transendothelial migration: unifying principles from the endothelial perspective","volume":"273","author":"Muller","year":"2016","journal-title":"Immunol Rev"},{"key":"10.1016\/j.blre.2022.100932_bb0150","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1600-065X.2007.00529.x","article-title":"Functional insights on the polarized redistribution of leukocyte integrins and their ligands during leukocyte migration and immune interactions","volume":"218","author":"Barreiro","year":"2007","journal-title":"Immunol Rev"},{"key":"10.1016\/j.blre.2022.100932_bb0155","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1160\/TH08-11-0714","article-title":"Endothelial adapter proteins in leukocyte transmigration","volume":"101","author":"Buul","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2022.100932_bb0160","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/nature07434","article-title":"Live-animal tracking of individual haematopoietic stem\/progenitor cells in their niche","volume":"457","author":"Lo Celso","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.blre.2022.100932_bb0165","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.immuni.2006.10.016","article-title":"Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches","volume":"25","author":"Sugiyama","year":"2006","journal-title":"Immunity"},{"key":"10.1016\/j.blre.2022.100932_bb0170","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.cell.2004.07.004","article-title":"Tie2\/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche","volume":"118","author":"Arai","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.blre.2022.100932_bb0175","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nature07639","article-title":"Detection of functional haematopoietic stem cell niche using real-time imaging","volume":"457","author":"Xie","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.blre.2022.100932_bb0180","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1182\/blood-2014-09-570192","article-title":"Making sense of hematopoietic stem cell niches","volume":"125","author":"Boulais","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.100932_bb0185","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/s41580-019-0103-9","article-title":"Haematopoietic stem cell activity and interactions with the niche","volume":"20","author":"Pinho","year":"2019","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.blre.2022.100932_bb0190","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nri.2017.53","article-title":"Adult haematopoietic stem cell niches","volume":"17","author":"Crane","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.blre.2022.100932_bb0195","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1016\/j.devcel.2021.05.018","article-title":"Niches that regulate stem cells and hematopoiesis in adult bone marrow","volume":"56","author":"Comazzetto","year":"2021","journal-title":"Dev Cell"},{"key":"10.1016\/j.blre.2022.100932_bb0200","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nature10783","article-title":"Endothelial and perivascular cells maintain haematopoietic stem cells","volume":"481","author":"Ding","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.blre.2022.100932_bb0205","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/jlb.66.1.25","article-title":"Adhesion and homing of blood-borne cells in bone marrow microvessels","volume":"66","author":"Mazo","year":"1999","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.blre.2022.100932_bb0210","first-page":"165","article-title":"Constitutive expression of E-selectin and vascular cell adhesion molecule-1 on endothelial cells of hematopoietic tissues","volume":"148","author":"Schweitzer","year":"1996","journal-title":"Am J Pathol"},{"key":"10.1016\/j.blre.2022.100932_bb0215","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1172\/JCI0214047","article-title":"Functional selectin ligands mediating human CD34(+) cell interactions with bone marrow endothelium are enhanced postnatally","volume":"110","author":"Hidalgo","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2022.100932_bb0220","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1182\/blood-2010-11-320705","article-title":"Analysis of glycoprotein E-selectin ligands on human and mouse marrow cells enriched for hematopoietic stem\/progenitor cells","volume":"118","author":"Merzaban","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.100932_bb0225","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1083\/jcb.153.6.1277","article-title":"CD44 is a major E-selectin ligand on human hematopoietic progenitor cells","volume":"153","author":"Dimitroff","year":"2001","journal-title":"J Cell Biol"},{"key":"10.1016\/j.blre.2022.100932_bb0230","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1182\/blood.V95.11.3289","article-title":"The chemokine SDF-1 activates the integrins LFA-1, VLA-4, and VLA-5 on immature human CD34(+) cells: role in transendothelial\/stromal migration and engraftment of NOD\/SCID mice","volume":"95","author":"Peled","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.100932_bb0235","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1182\/blood-2003-12-4157","article-title":"Integrin alpha4beta7 and its counterreceptor MAdCAM-1 contribute to hematopoietic progenitor recruitment into bone marrow following transplantation","volume":"104","author":"Katayama","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.100932_bb0240","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1182\/blood-2017-06-780882","article-title":"Inflammation: a key regulator of hematopoietic stem cell fate in health and disease","volume":"130","author":"Pietras","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.100932_bb0245","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.635189","article-title":"The dynamic interface between the bone marrow vascular niche and hematopoietic stem cells in myeloid malignancy","volume":"9","author":"Mosteo","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.blre.2022.100932_bb0250","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1126\/scitranslmed.3004315","article-title":"Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia","volume":"4","author":"Jan","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.blre.2022.100932_bb0255","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood.2019004397","article-title":"Preleukemic and leukemic evolution at the stem cell level","volume":"137","author":"Stauber","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.100932_bb0260","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1172\/JCI41495","article-title":"Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD\/SCID\/IL2R\u03b3c-deficient mice","volume":"121","author":"Sarry","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2022.100932_bb0265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1196\/annals.1349.001","article-title":"Acute myeloid leukemia stem cells","volume":"1044","author":"Dick","year":"2005","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.blre.2022.100932_bb0270","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/gcc.22805","article-title":"The cell of origin and the leukemia stem cell in acute myeloid leukemia","volume":"58","author":"Chopra","year":"2019","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.blre.2022.100932_bb0275","doi-asserted-by":"crossref","first-page":"248","DOI":"10.20892\/j.issn.2095-3941.2016.0023","article-title":"Bone marrow niche-mediated survival of leukemia stem cells in acute myeloid leukemia: Yin and Yang","volume":"13","author":"Zhou","year":"2016","journal-title":"Cancer Biol Med"},{"key":"10.1016\/j.blre.2022.100932_bb0280","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1182\/blood-2014-04-570762","article-title":"Endothelial cells translate pathogen signals into G-CSF-driven emergency granulopoiesis","volume":"124","author":"Boettcher","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.100932_bb0285","doi-asserted-by":"crossref","first-page":"5327","DOI":"10.1038\/s41467-020-19119-8","article-title":"Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics","volume":"11","author":"Morita","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2022.100932_bb0290","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ccr.2014.01.031","article-title":"Functional heterogeneity of genetically defined subclones in acute myeloid leukemia","volume":"25","author":"Klco","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.blre.2022.100932_bb0295","article-title":"CD44 engagement enhances acute myeloid leukemia cell adhesion to the bone marrow microenvironment by increasing VLA-4 avidity","author":"Gutjahr","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2022.100932_bb0300","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1038\/leu.2014.109","article-title":"Functional integration of acute myeloid leukemia into the vascular niche","volume":"28","author":"Cogle","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2022.100932_bb0305","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1182\/blood-2013-06-511527","article-title":"Reciprocal leukemia-stroma VCAM-1\/VLA-4-dependent activation of NF-\u03baB mediates chemoresistance","volume":"123","author":"Jacamo","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.100932_bb0310","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1038\/nm909","article-title":"Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia","volume":"9","author":"Matsunaga","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2022.100932_bb0315","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1182\/blood.V99.1.290","article-title":"Effects of anti-CD44 monoclonal antibodies on differentiation and apoptosis of human myeloid leukemia cell lines","volume":"99","author":"Charrad","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.100932_bb0320","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1038\/leu.2016.221","article-title":"Anti-CD44 antibodies inhibit both mTORC1 and mTORC2: a new rationale supporting CD44-induced AML differentiation therapy","volume":"30","author":"Gadhoum","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2022.100932_bb0325","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1038\/nm.2969","article-title":"Vascular niche E-selectin regulates hematopoietic stem cell dormancy, self renewal and chemoresistance","volume":"18","author":"Winkler","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2022.100932_bb0330","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1038\/s41467-020-15817-5","article-title":"Endothelial E-selectin inhibition improves acute myeloid leukaemia therapy by disrupting vascular niche-mediated chemoresistance","volume":"11","author":"Barbier","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2022.100932_bb0335","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1182\/blood.V124.21.620.620","article-title":"Vascular niche E-selectin protects acute myeloid leukaemia stem cells from chemotherapy","volume":"124","author":"Winkler","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.100932_bb0340","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11091253","article-title":"Acute myeloid and lymphoblastic leukemia cell interactions with endothelial selectins: critical role of PSGL-1, CD44 and CD43","volume":"11","author":"Spertini","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.blre.2022.100932_bb0345","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1309\/AJCP34YERPZSCYKQ","article-title":"Discordant immunophenotypic profiles of adhesion molecules and cytokines in acute myeloid leukemia involving bone marrow and skin","volume":"138","author":"Sachdev","year":"2012","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.blre.2022.100932_bb0350","doi-asserted-by":"crossref","first-page":"668","DOI":"10.3389\/fcell.2020.00668","article-title":"Acute myeloid leukemia chemo-resistance is mediated by E-selectin receptor CD162 in bone marrow niches","volume":"8","author":"Erbani","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.blre.2022.100932_bb0355","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/bjh.16456","article-title":"Dissecting the role of the CXCL12\/CXCR4 axis in acute myeloid leukaemia","volume":"189","author":"Ladikou","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2022.100932_bb0360","doi-asserted-by":"crossref","first-page":"4523","DOI":"10.1182\/blood.V91.12.4523","article-title":"The chemokine receptor CXCR-4 is expressed on CD34+ hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1","author":"Mohle","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.100932_bb0365","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3324\/haematol.10148","article-title":"Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells","author":"Bruserud","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2022.100932_bb0370","first-page":"149","article-title":"The chemokine network in acute myelogenous leukemia: molecular mechanisms involved in leukemogenesis and therapeutic implications","author":"Kittang","year":"2010","journal-title":"Curr Topics Microbiol Immunol."},{"key":"10.1016\/j.blre.2022.100932_bb0375","doi-asserted-by":"crossref","first-page":"6215","DOI":"10.1182\/blood-2008-05-158311","article-title":"Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML","author":"Zeng","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.100932_bb0380","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1080\/10245332.2017.1402455","article-title":"TGF-beta1 and CXCL12 modulate proliferation and chemotherapy sensitivity of acute myeloid leukemia cells co-cultured with multipotent mesenchymal stromal cells","author":"Schelker","year":"2018","journal-title":"Hematology"},{"key":"10.1016\/j.blre.2022.100932_bb0385","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1182\/blood-2013-06-511527","article-title":"Reciprocal leukemia-stroma VCAM-1\/VLA-4-dependent activation of NF-jB mediates chemoresistance","author":"Jacomo","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.100932_bb0390","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1182\/blood-2004-02-0566","article-title":"Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia","author":"Rombouts","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.100932_bb0395","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1182\/blood-2006-05-024844","article-title":"CXCR4 is a prognostic marker in acute myelogenous leukemia","author":"Spoo","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.100932_bb0400","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1002\/cncr.22510","article-title":"Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype","author":"Konoplev","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2022.100932_bb0405","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5507\/bp.2014.049","article-title":"The role of adhesion molecules in acute myeloid leukemia and (hemato)oncology: a systematic review","volume":"159","author":"Kupsa","year":"2015","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"key":"10.1016\/j.blre.2022.100932_bb0410","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0163982","article-title":"Extracellular histone released from leukemic cells increases their adhesion to endothelium and protects them from spontaneous and chemotherapy-induced leukemic cell death","volume":"11","author":"Yoo","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.blre.2022.100932_bb0415","article-title":"Adhesion deregulation in acute myeloid leukaemia","volume":"8","author":"Gruszka","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.blre.2022.100932_bb0420","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nrc2714","article-title":"Environment-mediated drug resistance: a major contributor to minimal residual disease","volume":"9","author":"Meads","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.blre.2022.100932_bb0425","doi-asserted-by":"crossref","DOI":"10.1100\/2012\/856467","article-title":"Dependence of acute myeloid leukemia on adhesion within the bone marrow microenvironment","volume":"2012","author":"Becker","year":"2012","journal-title":"Scient World J"},{"key":"10.1016\/j.blre.2022.100932_bb0430","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.592733","article-title":"Cadherins, selectins, and integrins in CAM-DR in leukemia","volume":"10","author":"Kim","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.blre.2022.100932_bb0435","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0060823","article-title":"Leukemia mediated endothelial cell activation modulates leukemia cell susceptibility to chemotherapy through a positive feedback loop mechanism","volume":"8","author":"Pezeshkian","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.blre.2022.100932_bb0440","first-page":"5","volume":"95","author":"Hussong","year":"2000","journal-title":"Evidence of increased angiogenesis in patients with acute myeloid leukemia"},{"key":"10.1016\/j.blre.2022.100932_bb0445","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1182\/blood.V95.8.2637","article-title":"Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia","volume":"95","author":"Padr\u00f3","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.100932_bb0450","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3892\/ol.2015.3209","article-title":"Levels of bone marrow microvessel density are crucial for evaluating the status of acute myeloid leukemia","volume":"10","author":"Song","year":"2015","journal-title":"Oncol Lett"},{"key":"10.1016\/j.blre.2022.100932_bb0455","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1038\/sj.leu.2402534","article-title":"Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia","volume":"16","author":"Padr\u00f3","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2022.100932_bb0460","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.3109\/10428194.2012.748907","article-title":"Prognostic significance of vascular endothelial growth factor expression in adult patients with acute myeloid leukemia: a meta-analysis","volume":"54","author":"Guo","year":"2013","journal-title":"Leukemia Lymphoma"},{"key":"10.1016\/j.blre.2022.100932_bb0465","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1309\/331QX7AXKWFJFKXM","article-title":"Immunohistochemical detection of VEGF in the bone marrow of patients with acute myeloid leukemia: correlation between VEGF expression and the FAB category","volume":"119","author":"Ghannadan","year":"2003","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.blre.2022.100932_bb0470","first-page":"149","article-title":"Circulating VEGF and its soluble receptors sVEGFR-1 and sVEGFR-2 in patients with acute leukemia","volume":"14","author":"Wierzbowska","year":"2003","journal-title":"Eur Cytokine Netw"},{"key":"10.1016\/j.blre.2022.100932_bb0475","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1089\/152581602753448586","article-title":"Blood levels of angiogenin and vascular endothelial growth factor are elevated in myelodysplastic syndromes and in acute myeloid leukemia","volume":"11","author":"Brunner","year":"2002","journal-title":"J Hematother Stem Cell Res"},{"key":"10.1016\/j.blre.2022.100932_bb0480","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nature13034","article-title":"Direct measurement of local oxygen concentration in the bone marrow of live animals","volume":"508","author":"Spencer","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.blre.2022.100932_bb0485","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1089\/scd.2015.0112","article-title":"Hypoxic niche-mediated regeneration of hematopoiesis in the engraftment window is dominantly affected by oxygen tension in the milieu","volume":"24","author":"Moirangthem","year":"2015","journal-title":"Stem Cells Dev."},{"key":"10.1016\/j.blre.2022.100932_bb0490","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1124\/mol.106.027029","article-title":"Hypoxia-inducible factor-1 (HIF-1)","volume":"70","author":"Ke","year":"2006","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.blre.2022.100932_bb0495","doi-asserted-by":"crossref","first-page":"6857","DOI":"10.3390\/ijms22136857","article-title":"The role of hypoxic bone marrow microenvironment in acute myeloid leukemia and future therapeutic opportunities","volume":"22","author":"Bruno","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.blre.2022.100932_bb0500","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.leukres.2010.10.020","article-title":"Hypoxia-inducible factor-1\u03b1 protein expression is associated with poor survival in normal karyotype adult acute myeloid leukemia","volume":"35","author":"Deeb","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2022.100932_bb0505","doi-asserted-by":"crossref","DOI":"10.15406\/htij.2017.04.00073","article-title":"Hypoxia-inducible factor 1 alpha (HIF-1\u03b1) and its prognostic value in acute myeloid leukemia","volume":"4","author":"Elhoseiny","year":"2017","journal-title":"HTIJ"},{"key":"10.1016\/j.blre.2022.100932_bb0510","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.exphem.2010.08.004","article-title":"Acquisition of G0 state by CD34-positive cord blood cells after bone marrow transplantation","volume":"38","author":"Shima","year":"2010","journal-title":"Exp Hematol"},{"key":"10.1016\/j.blre.2022.100932_bb0515","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2174\/157016112798829760","article-title":"The role of nitric oxide on endothelial function","volume":"10","author":"Tousoulis","year":"2012","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.blre.2022.100932_bb0520","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ccell.2017.08.001","article-title":"Increased vascular permeability in the bone marrow microenvironment contributes to disease progression and drug response in acute myeloid leukemia","volume":"32","author":"Passaro","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.blre.2022.100932_bb0525","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1080\/14728222.2018.1486821","article-title":"How to say NO to vascular disruption and stem cell mobilization","volume":"22","author":"Passaro","year":"2018","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.blre.2022.100932_bb0530","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1038\/nm.3960","article-title":"PAR1 signaling regulates the retention and recruitment of EPCR-expressing bone marrow hematopoietic stem cells","volume":"21","author":"Gur-Cohen","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2022.100932_bb0535","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1007\/s00018-012-1085-3","article-title":"Vascular endothelial growth factor signaling in acute myeloid leukemia","volume":"70","author":"Kampen","year":"2013","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.blre.2022.100932_bb0540","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.canlet.2015.05.007","article-title":"Acute myeloid leukemia in the vascular niche","volume":"380","author":"Cogle","year":"2016","journal-title":"Cancer Lett"},{"key":"10.1016\/j.blre.2022.100932_bb0545","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1200\/JCO.1987.5.9.1364","article-title":"Hyperleukocytosis in adult acute nonlymphocytic leukemia: impact on remission rate and duration, and survival","volume":"5","author":"Dutcher","year":"1987","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2022.100932_bb0550","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/ajh.2830270109","article-title":"Acute myeloblastic leukemia with hyperleukocytosis: risk factors for early mortality in induction","volume":"27","author":"Ventura","year":"1988","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2022.100932_bb0555","first-page":"1007","article-title":"Factors affecting survival of patients with acute myelocytic leukemia presenting with high wbc counts","volume":"65","author":"Vaughan","year":"1981","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.blre.2022.100932_bb0560","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1002\/1097-0142(19830901)52:5<773::AID-CNCR2820520503>3.0.CO;2-X","article-title":"Clinical course and response to treatment of patients with acute myelogenous leukemia presenting with a high leukocyte count","volume":"52","author":"Hug","year":"1983","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2022.100932_bb0565","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1182\/blood-2014-10-551507","article-title":"How I treat hyperleukocytosis in acute myeloid leukemia","volume":"125","author":"R\u00f6llig","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.100932_bb0570","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1080\/17474086.2017.1270754","article-title":"Hyperleukocytosis and leukostasis: management of a medical emergency","volume":"10","author":"Giammarco","year":"2017","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.blre.2022.100932_bb0575","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1600-0609.2005.00421.x","article-title":"Grading of symptoms in hyperleukocytic leukaemia: a clinical model for the role of different blast types and promyelocytes in the development of leukostasis syndrome","volume":"74","author":"Novotny","year":"2005","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2022.100932_bb0580","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1080\/10428190600572673","article-title":"Leukocyte count as a predictor of death during remission induction in acute myeloid leukemia","volume":"47","author":"Greenwood","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2022.100932_bb0585","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.leukres.2008.01.004","article-title":"Outcome of hyperleukocytic adult acute myeloid leukaemia: a single-center retrospective study and review of literature","volume":"32","author":"Marbello","year":"2008","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2022.100932_bb0590","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.3109\/10428194.2014.887709","article-title":"Respiratory events at the earliest phase of acute myeloid leukemia","volume":"55","author":"Moreau","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2022.100932_bb0595","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/0002-9343(80)90467-2","article-title":"Association of monocytic leukemia in patients with extreme leukocytosis","volume":"69","author":"Cuttner","year":"1980","journal-title":"Am J Med"},{"key":"10.1016\/j.blre.2022.100932_bb0600","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1182\/blood.V67.2.484.484","article-title":"Clinical and hematologic characteristics in acute leukemia with 11q23 translocations","volume":"67","author":"Kaneko","year":"1986","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.100932_bb0605","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1182\/blood.V99.12.4326","article-title":"Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis","volume":"99","author":"Thiede","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.100932_bb0610","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-020-0783-3","article-title":"Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study","author":"Stahl","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2022.100932_bb0615","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"New Engl J Med."},{"key":"10.1016\/j.blre.2022.100932_bb0620","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0055870","article-title":"Acute kidney injury in patients with newly diagnosed high-grade hematological malignancies: impact on remission and survival","volume":"8","author":"Canet","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.blre.2022.100932_bb0625","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1002\/cncr.25306","article-title":"Predictors and outcome of acute kidney injury in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome","volume":"116","author":"Lahoti","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2022.100932_bb0630","doi-asserted-by":"crossref","first-page":"x97","DOI":"10.1093\/annonc\/mdx664.011","article-title":"Acute kidney injury in newly diagnosed acute myeloid leukemia patients undergoing remission induction chemotherapy: experience of a tertiary cancer centre of India","volume":"28","author":"Kumar","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.blre.2022.100932_bb0635","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/(SICI)1097-0142(19990115)85:2<368::AID-CNCR14>3.0.CO;2-X","article-title":"Leukostasis followed by hemorrhage complicating the initiation of chemotherapy in patients with acute myeloid leukemia and hyperleukocytosis: a clinicopathologic report of four cases","volume":"85","author":"W\u00fcrthner","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2022.100932_bb0640","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1172\/JCI107191","article-title":"Rheology of leukocytes, leukocyte suspensions, and blood in leukemia. Possible relationship to clinical manifestations","volume":"52","author":"Lichtman","year":"1973","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2022.100932_bb0645","first-page":"1","article-title":"Leukocytapheresis for patients with acute myeloid leukemia presenting with hyperleukocytosis and leukostasis: a contemporary appraisal of outcomes and benefits","author":"Shallis","year":"2020","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.blre.2022.100932_bb0650","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/ajh.2830400106","article-title":"Pulmonary leukostasis without hyperleukocytosis: a clinicopathologic study of 16 cases","volume":"40","author":"Soares","year":"1992","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2022.100932_bb0655","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1164\/rccm.200206-554OC","article-title":"Acute monocytic leukemia presenting as acute respiratory failure","volume":"167","author":"Azoulay","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.blre.2022.100932_bb0660","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/ajh.20526","article-title":"Expression of MAC-1 (CD11b) in acute myeloid leukemia (AML) is associated with an unfavorable prognosis","volume":"81","author":"Graf","year":"2006","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2022.100932_bb0665","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2147\/CMAR.S125259","article-title":"Symptomatic central nervous system involvement in adult patients with acute myeloid leukemia","volume":"9","author":"Alakel","year":"2017","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.blre.2022.100932_bb0670","doi-asserted-by":"crossref","DOI":"10.35248\/2329-6917.19.7.257","article-title":"Primary and secondary central nervous system involvement in acute myeloid leukemia","volume":"07","author":"Patkowska","year":"2019","journal-title":"J Leuk"},{"key":"10.1016\/j.blre.2022.100932_bb0675","article-title":"Myeloid sarcoma, chloroma, or extramedullary acute myeloid leukemia tumor: a tale of misnomers, controversy and the unresolved","volume":"100773","author":"Shallis","year":"2020","journal-title":"Blood Rev."},{"key":"10.1016\/j.blre.2022.100932_bb0680","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.3324\/haematol.2019.223032","article-title":"The prevalence of extramedullary acute myeloid leukemia detected by 18FDG-PET\/CT: final results from the prospective PETAML trial","volume":"105","author":"St\u00f6lzel","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2022.100932_bb0685","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1182\/blood-2008-04-148643","article-title":"Role of leukemia cell invadosome in extramedullary infiltration","volume":"114","author":"Stefanidakis","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.100932_bb0690","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1378\/chest.98.5.1233","article-title":"Pulmonary complications of leukemia","volume":"98","author":"Fredric","year":"1990","journal-title":"Chest"},{"key":"10.1016\/j.blre.2022.100932_bb0695","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00277-018-3494-3","article-title":"Autopsy findings in patients with acute myeloid leukemia and non-Hodgkin lymphoma in the modern era: a focus on lung pathology and acute respiratory failure","volume":"98","author":"Van de Louw","year":"2019","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2022.100932_bb0700","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1093\/ckj\/sft066","article-title":"Infiltrative acute myeloid leukaemia as a cause of acute kidney injury","volume":"6","author":"Ooi","year":"2013","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.blre.2022.100932_bb0705","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/00043426-200201000-00015","article-title":"Presentation of M4 acute myeloid leukemia in anuric renal failure with hyperuricemia and enlarged kidneys","volume":"24","author":"Duda","year":"2002","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.blre.2022.100932_bb0710","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/1097-0142(19870815)60:4<827::AID-CNCR2820600419>3.0.CO;2-A","article-title":"An autopsy study of 1206 acute and chronic leukemias (1958 to 1982)","volume":"60","author":"Barcos","year":"1987","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2022.100932_bb0715","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1590\/abd1806-4841.20186327","article-title":"Clinical and pathological features of myeloid leukemia cutis","volume":"93","author":"Li","year":"2018","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.blre.2022.100932_bb0720","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1001\/jamadermatol.2019.0052","article-title":"Association of leukemia cutis with survival in acute myeloid leukemia","volume":"155","author":"Wang","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.blre.2022.100932_bb0725","series-title":"Leukemia Cutis","author":"Parsi","year":"2020"},{"key":"10.1016\/j.blre.2022.100932_bb0730","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1309\/WYACYWF6NGM3WBRT","article-title":"Leukemia cutis","volume":"129","author":"Cho-Vega","year":"2008","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.blre.2022.100932_bb0735","doi-asserted-by":"crossref","first-page":"S206","DOI":"10.1016\/j.bbmt.2015.11.600","article-title":"Characteristics and survival outcome analysis of central nervous system involvement in adult patients with acute myeloid leukemia","volume":"22","author":"Park","year":"2016","journal-title":"Biol Blood Marrow Transplant."},{"key":"10.1016\/j.blre.2022.100932_bb0740","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.bbmt.2014.11.683","article-title":"Central nervous system involvement in acute myeloid leukemia patients undergoing hematopoietic cell transplantation","volume":"21","author":"Bar","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2022.100932_bb0745","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1186\/s12885-015-1376-9","article-title":"Risk factors and clinical outcomes of acute myeloid leukaemia with central nervous system involvement in adults","volume":"15","author":"Cheng","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.blre.2022.100932_bb0750","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/0002-9343(87)90756-X","article-title":"Central nervous system involvement in acute nonlymphocytic leukemia. A prospective study of adults in remission","volume":"83","author":"Peterson","year":"1987","journal-title":"Am J Med"},{"key":"10.1016\/j.blre.2022.100932_bb0755","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.canlet.2007.09.004","article-title":"Targeting the neural cell adhesion molecule in cancer","volume":"258","author":"Jensen","year":"2007","journal-title":"Cancer Lett"},{"key":"10.1016\/j.blre.2022.100932_bb0760","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.leukres.2004.01.006","article-title":"Extramedullary infiltrates of AML are associated with CD56 expression, 11q23 abnormalities and inferior clinical outcome","volume":"28","author":"Chang","year":"2004","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2022.100932_bb0765","doi-asserted-by":"crossref","first-page":"202","DOI":"10.5581\/1516-8484.20110054","article-title":"The expression of CD56 antigen is associated with poor prognosis in patients with acute myeloid leukemia","volume":"33","author":"Alegretti","year":"2011","journal-title":"Rev Bras Hematol Hemoter"},{"key":"10.1016\/j.blre.2022.100932_bb0770","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/0145-2126(92)90017-2","article-title":"Myeloblastoma formation in acute myeloid leukemia","volume":"16","author":"Iizuka","year":"1992","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2022.100932_bb0775","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.leukres.2013.05.002","article-title":"CD56 expression is an independent prognostic factor for relapse in acute myeloid leukemia with t(8;21)","volume":"37","author":"Iriyama","year":"2013","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2022.100932_bb0780","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1309\/AJCPBS3W1RJDGPZU","article-title":"Minimal coexpression of CD34+\/CD56+ in acute promyelocytic leukemia is associated with relapse","volume":"144","author":"Maenhout","year":"2015","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.blre.2022.100932_bb0785","doi-asserted-by":"crossref","first-page":"68","DOI":"10.21037\/atm-20-3140","article-title":"A narrative review of central nervous system involvement in acute leukemias","volume":"9","author":"Deak","year":"2021","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.blre.2022.100932_bb0790","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.1007\/s00018-008-8290-0","article-title":"Signaling mechanisms of neurite outgrowth induced by the cell adhesion molecules NCAM and N-cadherin","volume":"65","author":"Hansen","year":"2008","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.blre.2022.100932_bb0795","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1111\/jth.15074","article-title":"Management of hemostatic complications in acute leukemia: guidance from the SSC of the ISTH","volume":"18","author":"Wang","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2022.100932_bb0800","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1177\/1076029607302435","article-title":"Disseminated intravascular coagulation in acute leukemia at presentation and during induction therapy","volume":"13","author":"Dixit","year":"2007","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.blre.2022.100932_bb0805","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1600-0609.2006.00711.x","article-title":"Disseminated intravascular coagulation in acute leukemia: clinical and laboratory features at presentation","volume":"77","author":"Yanada","year":"2006","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2022.100932_bb0810","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1532\/IJH97.06173","article-title":"Prevalence and clinical characteristics of acute myeloid leukemia associated with disseminated intravascular coagulation","volume":"86","author":"Uchiumi","year":"2007","journal-title":"Int J Hematol"},{"key":"10.1016\/j.blre.2022.100932_bb0815","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1182\/blood-2016-02-701094","article-title":"Disseminated intravascular coagulation at diagnosis is a strong predictor for thrombosis in acute myeloid leukemia","volume":"128","author":"Libourel","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.100932_bb0820","doi-asserted-by":"crossref","DOI":"10.3390\/cells9102310","article-title":"Hyperleukocytosis and leukostasis in acute myeloid leukemia: can a better understanding of the underlying molecular pathophysiology lead to novel treatments?","volume":"9","author":"Bewersdorf","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.blre.2022.100932_bb0825","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1073\/pnas.83.10.3460","article-title":"Interleukin 1 induces endothelial cell procoagulant while suppressing cell-surface anticoagulant activity","volume":"83","author":"Nawroth","year":"1986","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2022.100932_bb0830","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/10623320490904124","article-title":"Differential toxicity of anthracyclines on cultured endothelial cells","volume":"11","author":"Kaushal","year":"2004","journal-title":"Endothelium"},{"key":"10.1016\/j.blre.2022.100932_bb0835","doi-asserted-by":"crossref","first-page":"33585","DOI":"10.1074\/jbc.M003890200","article-title":"Doxorubicin-induced apoptosis in endothelial cells and cardiomyocytes is ameliorated by nitrone spin traps and ebselen. Role of reactive oxygen and nitrogen species","volume":"275","author":"Kotamraju","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.blre.2022.100932_bb0840","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.bbagen.2005.10.012","article-title":"The anti-cancer drug, doxorubicin, causes oxidant stress-induced endothelial dysfunction","volume":"1760","author":"Wolf","year":"2006","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.blre.2022.100932_bb0845","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.pharep.2015.03.022","article-title":"Detrimental effects of chemotherapeutics and other drugs on the endothelium: a call for endothelial toxicity profiling","volume":"67","author":"Wojcik","year":"2015","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.blre.2022.100932_bb0850","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jacbts.2018.06.005","article-title":"Role of endothelium in doxorubicin-induced cardiomyopathy","volume":"3","author":"Luu","year":"2018","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.blre.2022.100932_bb0855","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2019.01531","article-title":"Doxorubicin induces endotheliotoxicity and mitochondrial dysfunction via ROS\/eNOS\/NO pathway","volume":"10","author":"He","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.blre.2022.100932_bb0860","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.thromres.2014.05.001","article-title":"Microparticle-associated tissue factor activity and overt disseminated intravascular coagulation in patients with acute myelocytic leukemia","volume":"134","author":"Gheldof","year":"2014","journal-title":"Thromb Res"},{"key":"10.1016\/j.blre.2022.100932_bb0865","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s11239-016-1471-z","article-title":"Procoagulant activity of extracellular vesicles as a potential biomarker for risk of thrombosis and DIC in patients with acute leukaemia","volume":"43","author":"Gheldof","year":"2017","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.blre.2022.100932_bb0870","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.thromres.2013.12.029","article-title":"Clinical evidence for a link between microparticle-associated tissue factor activity and overt disseminated intravascular coagulation in patients with acute myelocytic leukemia","volume":"133","author":"Thaler","year":"2014","journal-title":"Thromb Res"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2022.100932_bb0875","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1016\/j.thromres.2018.01.041","article-title":"Mechanisms and management of coagulopathy in acute promyelocytic leukemia","volume":"164","author":"David","year":"2018","journal-title":"Thromb Res"},{"key":"10.1016\/j.blre.2022.100932_bb0880","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/MOH.0000000000000221","article-title":"What\u2019s new in the pathogenesis of the coagulopathy in acute promyelocytic leukemia?","volume":"23","author":"Mantha","year":"2016","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.blre.2022.100932_bb0885","doi-asserted-by":"crossref","DOI":"10.1186\/s12959-020-00231-0","article-title":"Disseminated intravascular coagulation: new identity as endotheliopathy-associated vascular microthrombotic disease based on in vivo hemostasis and endothelial molecular pathogenesis","volume":"18","author":"Chang","year":"2020","journal-title":"Thromb J"},{"key":"10.1016\/j.blre.2022.100932_bb0890","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s12032-013-0478-y","article-title":"International Society of Thrombosis and Hemostasis Scoring System for disseminated intravascular coagulation \u2265 6: a new predictor of hemorrhagic early death in acute promyelocytic leukemia","volume":"30","author":"Mitrovic","year":"2013","journal-title":"Med Oncol"},{"key":"10.1016\/j.blre.2022.100932_bb0895","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1600-0609.2011.01747.x","article-title":"Clinical bleeding events and laboratory coagulation profiles in acute promyelocytic leukemia","volume":"88","author":"Chang","year":"2012","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2022.100932_bb0900","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1182\/blood.2019001239","article-title":"How I treat acute myeloid leukemia in the era of new drugs","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.100932_bb0905","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1592\/phco.20.17.1396.34897","article-title":"Corticosteroids and serious cytarabine-induced pulmonary edema","volume":"20","author":"Larouche","year":"2000","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.blre.2022.100932_bb0910","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1365-2141.2009.07895.x","article-title":"A new pattern of cytosine-arabinoside-induced lung toxicity","volume":"147","author":"Chagnon","year":"2009","journal-title":"Brit J Haematol"},{"key":"10.1016\/j.blre.2022.100932_bb0915","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1002\/1097-0142(19900301)65:5<1079::AID-CNCR2820650506>3.0.CO;2-K","article-title":"Fatal pulmonary failure complicating high-dose cytosine arabinoside therapy in acute leukemia","volume":"65","author":"Andersson","year":"1990","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2022.100932_bb0920","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1002\/1097-0142(19851101)56:9<2181::AID-CNCR2820560907>3.0.CO;2-B","article-title":"Subacute pulmonary failure complicating therapy with high-dose Ara-C in acute leukemia","volume":"56","author":"Andersson","year":"1985","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2022.100932_bb0925","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1111\/ijd.14392","article-title":"Chemotherapy-induced skin toxicity and capillary leak syndrome","volume":"58","author":"Hunjan","year":"2019","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.blre.2022.100932_bb0930","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.3324\/haematol.11697","article-title":"Cytarabine-related lung infiltrates on high resolution computerized tomography: a possible complication with benign outcome in leukemic patients","volume":"92","author":"Forghieri","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2022.100932_bb0935","article-title":"Tumor lysis syndrome and acute kidney injury: beyond crystal mechanisms","author":"Arnaud","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.blre.2022.100932_bb0940","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1189\/jlb.1003505","article-title":"Mechanisms of glucocorticoid-induced down-regulation of neutrophil L-selectin in cattle: evidence for effects at the gene-expression level and primarily on blood neutrophils","volume":"75","author":"Weber","year":"2004","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.blre.2022.100932_bb0945","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1161\/01.CIR.98.21.2307","article-title":"Glucocorticoid-induced granulocytosis: contribution of marrow release and demargination of intravascular granulocytes","volume":"98","author":"Nakagawa","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.blre.2022.100932_bb0950","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1183\/09031936.00057711","article-title":"Dexamethasone in patients with acute lung injury from acute monocytic leukaemia","volume":"39","author":"Azoulay","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.blre.2022.100932_bb0955","doi-asserted-by":"crossref","first-page":"988","DOI":"10.3324\/haematol.2017.184267","article-title":"Dexamethasone in hyperleukocytic acute myeloid leukemia","volume":"103","author":"Bertoli","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2022.100932_bb0960","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.2174\/156800911798073078","article-title":"Clinical experience with antiangiogenic therapy in leukemia","volume":"11","author":"Wellbrock","year":"2011","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.blre.2022.100932_bb0965","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/sj.leu.2404632","article-title":"Bevacizumab reduces VEGF expression in patients with relapsed and refractory acute myeloid leukemia without clinical antileukemic activity","volume":"21","author":"Zahiragic","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2022.100932_bb0970","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1158\/1078-0432.CCR-03-0627","article-title":"Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab","volume":"10","author":"Karp","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2022.100932_bb0975","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1182\/blood-2012-04-420596","article-title":"Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK)","volume":"120","author":"Ossenkoppele","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.100932_bb0980","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s10456-021-09797-3","article-title":"Endothelial cell plasticity at the single-cell level","volume":"24","author":"Pasut","year":"2021","journal-title":"Angiogenesis"},{"key":"10.1016\/j.blre.2022.100932_bb0985","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-021-01179-4","article-title":"Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603\/RATIFY trial","author":"Larson","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2022.100932_bb0990","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1200\/JCO.2012.46.4990","article-title":"Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial","volume":"31","author":"Serve","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2022.100932_bb0995","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/cncr.32534","article-title":"Sorafenib and omacetaxine mepesuccinate as a safe and effective treatment for acute myeloid leukemia carrying internal tandem duplication of Fms-like tyrosine kinase 3","volume":"126","author":"Zhang","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2022.100932_bb1000","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/bmt.2016.251","article-title":"Inhibition of FLT3 in AML: a focus on sorafenib","volume":"52","author":"Antar","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2022.100932_bb1005","doi-asserted-by":"crossref","first-page":"19059","DOI":"10.1073\/pnas.1318022110","article-title":"Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation","volume":"110","author":"Batchelor","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2022.100932_bb1010","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/nm.3289","article-title":"Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy","volume":"19","author":"Emblem","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2022.100932_bb1015","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1073\/pnas.1424024112","article-title":"Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer","volume":"112","author":"Heist","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2022.100932_bb1020","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/annonc\/mdw561","article-title":"Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study","volume":"28","author":"Faivre","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.blre.2022.100932_bb1025","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0140-6736(12)61857-1","article-title":"Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Demetri","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2022.100932_bb1030","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2022.100932_bb1035","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial","volume":"384","author":"Brose","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2022.100932_bb1040","article-title":"Reengineering the tumor microenvironment to alleviate hypoxia and overcome cancer heterogeneity","volume":"6","author":"Martin","year":"2016","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.blre.2022.100932_bb1045","doi-asserted-by":"crossref","first-page":"5158","DOI":"10.1182\/blood-2019-123472","article-title":"Apatinib exhibits cytotoxicity to acute myeloid leukemia cell via targeting VEGFR2-mediated pro-survival signaling and angiogenesis","volume":"134","author":"Yu","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.100932_bb1050","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2020.111934","article-title":"Apatinib exhibits cytotoxicity toward leukemia cells by targeting VEGFR2-mediated prosurvival signaling and angiogenesis","volume":"390","author":"Deng","year":"2020","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.blre.2022.100932_bb1055","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13020335","article-title":"Targeting E-selectin to tackle cancer using uproleselan","volume":"13","author":"Muz","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.blre.2022.100932_bb1060","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1080\/1042819042000206687","article-title":"The effect of anti-CD44 monoclonal antibodies on differentiation and proliferation of human acute myeloid leukemia cells","volume":"45","author":"Gadhoum","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2022.100932_bb1065","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/nm1483","article-title":"Targeting of CD44 eradicates human acute myeloid leukemic stem cells","volume":"12","author":"Jin","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2022.100932_bb1070","doi-asserted-by":"crossref","first-page":"32532","DOI":"10.18632\/oncotarget.8687","article-title":"Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia","volume":"7","author":"Vey","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.blre.2022.100932_bb1075","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.bcmd.2016.03.009","article-title":"AMD3100 and G-CSF disrupt the cross-talk between leukemia cells and the endosteal niche and enhance their sensitivity to chemotherapeutic drugs in biomimetic polystyrene scaffolds","author":"Shen","year":"2016","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.blre.2022.100932_bb1080","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.exphem.2010.11.010","article-title":"CXCR4 antagonist 4F-benzoyl-TN14003 inhibits leukemia and multiple myeloma tumor growth","author":"Beider","year":"2011","journal-title":"Exp Hematol"},{"key":"10.1016\/j.blre.2022.100932_bb1085","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1182\/blood-2015-02-628677","article-title":"Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy","author":"Cho","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.100932_bb1090","unstructured":"Kuhne MR, Mulvey T, Belanger B, Chen S, Pan C, Chong C, et al. BMS-936564\/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies. n.d."},{"key":"10.1016\/j.blre.2022.100932_bb1095","doi-asserted-by":"crossref","first-page":"24515","DOI":"10.1074\/jbc.M200889200","article-title":"A point mutation that confers constitutive activity to CXCR4 reveals that T140 is an inverse agonist and that AMD3100 and ALX40-4C are weak partial agonists","volume":"277","author":"Zhang","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.blre.2022.100932_bb1100","doi-asserted-by":"crossref","first-page":"6206","DOI":"10.1182\/blood-2008-06-162123","article-title":"Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100","author":"Nervi","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.100932_bb1105","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s00277-018-3229-5","article-title":"A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia","volume":"97","author":"Mart\u00ednez-Cuadr\u00f3n","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2022.100932_bb1110","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1182\/blood.V124.21.386.386","article-title":"Targeting the CXCR4 pathway: safety, tolerability and clinical activity of ulocuplumab (BMS-936564), an anti-CXCR4 antibody, in relapsed\/refractory acute myeloid leukemia","volume":"124","author":"Becker","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.100932_bb1115","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3389\/fonc.2018.00369","article-title":"Initial report of a phase I study of LY2510924, idarubicin, and cytarabine in relapsed\/refractory acute myeloid leukemia","volume":"8","author":"Boddu","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.blre.2022.100932_bb1120","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/cncr.33338","article-title":"BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed\/refractory acute myelogenous leukemia: an open-label safety and efficacy phase 2a study","volume":"127","author":"Borthakur","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2022.100932_bb1125","author":"University Hospital"},{"key":"10.1016\/j.blre.2022.100932_bb1130","doi-asserted-by":"crossref","unstructured":"Karp JE, Gojo I, Pili R, Gocke CD, Greer J, Guo C, et al. Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-\u2424-D-arabinofuranosylcytosine, mitoxantrone, and bevacizumab n.d.:10.","DOI":"10.1158\/1078-0432.CCR-03-0627"},{"key":"10.1016\/j.blre.2022.100932_bb1135","author":"University of Washington"},{"key":"10.1016\/j.blre.2022.100932_bb1140","author":"National Cancer Institute (NCI)"},{"key":"10.1016\/j.blre.2022.100932_bb1145","author":"GlycoMimetics Incorporated"},{"key":"10.1016\/j.blre.2022.100932_bb1150","author":"AGC Biologics S.p.A"},{"key":"10.1016\/j.blre.2022.100932_bb1155","author":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X22000066?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X22000066?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:28:20Z","timestamp":1759436900000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X22000066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":231,"alternative-id":["S0268960X22000066"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2022.100932","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Endothelial cells: major players in acute myeloid leukaemia","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2022.100932","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100932"}}